High-dose melphalan for multiple myeloma: Long-term follow-up data
Authors: Cunningham, D., Hickish, T. et al.
Journal: Journal of Clinical Oncology
Volume: 12
Issue: 4
Pages: 764-768
ISSN: 0732-183X
DOI: 10.1200/JCO.1994.12.4.764
Abstract:Purpose: To present long-term follow-up data of patients with myeloma treated with high-dose melphalan HDM, including an assessment of prognostic factors. Patients and Methods: Between November 1981 and April 1986, 63 previously untreated patients with multiple myeloma received HDM 140 mg/m2 without autologous bone marrow transplantation. Results: The overall response rate was 82% (51 of 62), with 32% (20 of 62) patients entering complete remission (CR). The median duration of response was 18 months, and six patients remain alive and free from disease progression at 60+ to 84+ months. Improvements in quality of life associated with remission were immediate in terms of pain grade (89% of patients) and performance status (92%), and later in terms of bone healing (29%). Currently, at a median follow-up duration of 74 months (range, 63 to 100) since HDM, 23 patients are alive with a median survival duration of 47 months, and 35% of patients are expected to be alive at 9 years. Apart from early-stage disease, no factors were found to predict long-term survival. No second malignancies or other late side effects have been recorded. Conclusion: Single-agent HDM without autologous bone marrow transplantation is a feasible therapeutic option in myeloma, and is associated with a high objective response rate, relatively long remission durations, and good symptom control.
Source: Scopus
High-dose melphalan for multiple myeloma: long-term follow-up data.
Authors: Cunningham, D., Paz-Ares, L., Gore, M.E., Malpas, J., Hickish, T., Nicolson, M., Meldrum, M., Viner, C., Milan, S. and Selby, P.J.
Journal: J Clin Oncol
Volume: 12
Issue: 4
Pages: 764-768
ISSN: 0732-183X
DOI: 10.1200/JCO.1994.12.4.764
Abstract:PURPOSE: To present long-term follow-up data of patients with myeloma treated with high-dose melphalan HDM, including an assessment of prognostic factors. PATIENTS AND METHODS: Between November 1981 and April 1986, 63 previously untreated patients with multiple myeloma received HDM 140 mg/m2 without autologous bone marrow transplantation. RESULTS: The overall response rate was 82% (51 of 62), with 32% (20 of 62) patients entering complete remission (CR). The median duration of response was 18 months, and six patients remain alive and free from disease progression at 60+ to 84+ months. Improvements in quality of life associated with remission were immediate in terms of pain grade (89% of patients) and performance status (92%), and later in terms of bone healing (29%). Currently, at a median follow-up duration of 74 months (range, 63 to 100) since HDM, 23 patients are alive with a median survival duration of 47 months, and 35% of patients are expected to be alive at 9 years. Apart from early-stage disease, no factors were found to predict long-term survival. No second malignancies or other late side effects have been recorded. CONCLUSION: Single-agent HDM without autologous bone marrow transplantation is a feasible therapeutic option in myeloma, and is associated with a high objective response rate, relatively long remission durations, and good symptom control.
Source: PubMed
Preferred by: Tamas Hickish
HIGH-DOSE MELPHALAN FOR MULTIPLE-MYELOMA - LONG-TERM FOLLOW-UP DATA
Authors: CUNNINGHAM, D., HICKISH, T. et al.
Journal: JOURNAL OF CLINICAL ONCOLOGY
Volume: 12
Issue: 4
Pages: 764-768
eISSN: 1527-7755
ISSN: 0732-183X
DOI: 10.1200/JCO.1994.12.4.764
Source: Web of Science (Lite)
High-dose melphalan for multiple myeloma: long-term follow-up data.
Authors: Cunningham, D., Paz-Ares, L., Gore, M.E., Malpas, J., Hickish, T., Nicolson, M., Meldrum, M., Viner, C., Milan, S. and Selby, P.J.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume: 12
Issue: 4
Pages: 764-768
eISSN: 1527-7755
ISSN: 0732-183X
DOI: 10.1200/jco.1994.12.4.764
Abstract:Purpose
To present long-term follow-up data of patients with myeloma treated with high-dose melphalan HDM, including an assessment of prognostic factors.Patients and methods
Between November 1981 and April 1986, 63 previously untreated patients with multiple myeloma received HDM 140 mg/m2 without autologous bone marrow transplantation.Results
The overall response rate was 82% (51 of 62), with 32% (20 of 62) patients entering complete remission (CR). The median duration of response was 18 months, and six patients remain alive and free from disease progression at 60+ to 84+ months. Improvements in quality of life associated with remission were immediate in terms of pain grade (89% of patients) and performance status (92%), and later in terms of bone healing (29%). Currently, at a median follow-up duration of 74 months (range, 63 to 100) since HDM, 23 patients are alive with a median survival duration of 47 months, and 35% of patients are expected to be alive at 9 years. Apart from early-stage disease, no factors were found to predict long-term survival. No second malignancies or other late side effects have been recorded.Conclusion
Single-agent HDM without autologous bone marrow transplantation is a feasible therapeutic option in myeloma, and is associated with a high objective response rate, relatively long remission durations, and good symptom control.Source: Europe PubMed Central